Catalyst

Slingshot members are tracking this event:

Lilly's (LLY) Olaratumab + Doxorubicin in Soft Tissue Sarcoma Recommended for Approval by European Ad Comm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
LLY

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords European Medicines Agency, Chmp, Olaratumab, Doxorubicin, Recommendation For Approval